Read the full article at Diabetes News From Medical News Today
Industry News Metabolic Type I Diabetes
Tolerx Completes Enrollment In DEFEND-1, A Phase 3 Type 1 Diabetes Study With Otelixizumab
Read the full article at Diabetes News From Medical News Today
